Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 90
Inquire Before Buying

Global Markets Direct's, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)

  • The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects

  • The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Interstitial Cystitis (Painful Bladder Syndrome) Overview 8
Therapeutics Development 9
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 9
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 10
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 11
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 12
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 16
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 17
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 18
Allergan Plc 19
Aquinox Pharmaceuticals Inc. 20
Astellas Pharma Inc. 21
Kytogenics Pharmaceuticals, Inc. 22
Lipella Pharmaceuticals, Inc. 23
MediPost Co., Ltd. 24
UCB S.A. 25
Urigen Pharmaceuticals, Inc. 26
UroGen Pharmaceuticals, Ltd. 27
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(heparin + lidocaine) - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AQX-1125 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ASP-6294 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Cartistem - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
certolizumab pegol - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
GM-0111 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
lidocaine hydrochloride - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
LP-08 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
mesalamine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
MK-7264 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
NEO-5937 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
onabotulinumtoxinA - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
onabotulinumtoxinA SR - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
pentosan polysulfate sodium - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
URG-801 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 77
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 78
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 79
Featured News & Press Releases 79
May 25, 2016: Aquinox Announces Executive Appointments 79
May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results 79
May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego 81
Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA 81
Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration 82
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference 82
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis 83
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS 84
Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84
Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84
Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis 85
May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms 85
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 86
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 87
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2016 9
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 18
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H2 2016 19
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016 20
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc., H2 2016 21
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2016 22
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016 23
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by MediPost Co., Ltd., H2 2016 24
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB S.A., H2 2016 25
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H2 2016 26
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 27
Assessment by Monotherapy Products, H2 2016 28
Assessment by Combination Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H2 2016 77
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H2 2016 78

List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2016 9
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Targets, H2 2016 30
Number of Products by Stage and Targets, H2 2016 30
Number of Products by Mechanism of Actions, H2 2016 32
Number of Products by Stage and Mechanism of Actions, H2 2016 32
Number of Products by Routes of Administration, H2 2016 34
Number of Products by Stage and Routes of Administration, H2 2016 34
Number of Products by Molecule Types, H2 2016 36
Number of Products by Stage and Molecule Types, H2 2016 36
  • Hyperoxaluria - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 44
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperoxaluria - Pipeline Review, H2 2016, provides an overview of the Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.Hyperoxaluria is defined by the presence of excess amounts of oxalic acid (oxalate) in the urine. Symptoms include severe or sudden abdominal or flank pain, blood in the urine, fever and chills, loss of appetite, nausea and vomiting. Treatment includes a low-oxalate di......
  • Global Urinary Incontinence Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Nov-2016        Price: US 3480 Onwards        Pages: 111
    Urinary incontinence products, such as pads, are not a cure for urinary incontinence; however, using these pads and other devices to contain urine loss and maintain skin integrity are extremely useful in selected cases. Absorbent products used include underpads, pant liners (shields and guards), adult diapers (briefs), a variety of washable pants, and disposable pad systems, or combinations of these products. Scope of the Report: This report focuses on the Urinary Incontine......
  • Toviaz -Drug Insights, 2016
    Published: 01-Nov-2016        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Toviaz- Drug Insights, 2016" highlights the Toviaz marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Toviaz covering the total sales estimation and also provides the Toviaz sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Toviaz, patents information and exclusivity......
  • Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Dysuria Report is to understand the market and pipeline status of the drugs around the Dysuria to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline start......
  • Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Interstitial Cystitis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, t......
  • Fistula-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Fistula-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Fistula. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, pat......
  • Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Nocturnal Enuresis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the re......
  • Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Interstitial Cystitis (Painful Bladder Syndrome) Report is to understand the market and pipeline status of the drugs around the Interstitial Cystitis (Painful Bladder Syndrome) to explore t......
  • Urinary Incontinence  - Epidemiology Forecast To 2023
    Published: 01-Nov-2016        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Urinary Incontinence - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Urinary Incontinence in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Urinary Incontinence prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs